Takahiro Miyamoto

Takahiro Miyamoto

Auto-generated profile, based on publicly available information

Takahiro Miyamoto

Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Recurrence and treatment resistance are major causes of cancer-associated death. There has been a growing interest in better understanding epithelial–mesenchymal transition, stemness of cancer cells, and exhaustion and dysfunction of the immune system for which numerous genomic, proteomic, microenvironmental, and immunologic mechanisms have been demonstrated. However, practical treatments for such patients have not yet been established. Here we identified IL33 as a key driver of polyploidy, followed by rapid proliferation after treatment. IL33 induction transformed tumor cells into polyploid giant cells, showing abnormal cell cycle without cell division accompanied by Snail deregulation and p53 inactivation; small progeny cells were generated in response to treatment stress. Simultaneously, soluble IL33 was released from tumor cells, leading to expansion of receptor ST2-expressing cells including IL17RB+GATA3+ cells, which promoted tumor progression and metastasis directly and indirectly via induction of immune exhaustion and dysfunction. Blocking IL33 with a specific mAb in murine IL33+ metastatic tumor models abrogated negative consequences and successfully elicited antitumor efficacy induced by other combined treatments. Ex vivo assays using tumor tissues and peripheral blood mononuclear cells of patients with cancer validated the clinical relevancy of these findings. Together, these data suggest that targeting the IL33-ST2 axis is a promising strategy for diagnosis and treatment of patients likely to be resistant to treatments in the clinical settings. Significance: These findings indicate that the functional role of IL33 in cancer polyploidy contributes to intrinsic and extrinsic mechanisms underlying treatment failure.

31 March 2023
Verified
Other
Open access
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Figure S1: Gating strategy for flow cytometric analysis, Figure S2: IL33 knockdown in human cancer cells, Figure S3: Establishment of IL33 transfectants using human cancer cells, Figure S4: The roles of IL17RB+ ILC2s in the IL33+ tumor progression, and Figure S5: Validation of polyploidy of murine cancer cells

31 March 2023
Verified
Other
Open access
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Recurrence and treatment resistance are major causes of cancer-associated death. There has been a growing interest in better understanding epithelial–mesenchymal transition, stemness of cancer cells, and exhaustion and dysfunction of the immune system for which numerous genomic, proteomic, microenvironmental, and immunologic mechanisms have been demonstrated. However, practical treatments for such patients have not yet been established. Here we identified IL33 as a key driver of polyploidy, followed by rapid proliferation after treatment. IL33 induction transformed tumor cells into polyploid giant cells, showing abnormal cell cycle without cell division accompanied by Snail deregulation and p53 inactivation; small progeny cells were generated in response to treatment stress. Simultaneously, soluble IL33 was released from tumor cells, leading to expansion of receptor ST2-expressing cells including IL17RB+GATA3+ cells, which promoted tumor progression and metastasis directly and indirectly via induction of immune exhaustion and dysfunction. Blocking IL33 with a specific mAb in murine IL33+ metastatic tumor models abrogated negative consequences and successfully elicited antitumor efficacy induced by other combined treatments. Ex vivo assays using tumor tissues and peripheral blood mononuclear cells of patients with cancer validated the clinical relevancy of these findings. Together, these data suggest that targeting the IL33-ST2 axis is a promising strategy for diagnosis and treatment of patients likely to be resistant to treatments in the clinical settings.Significance:These findings indicate that the functional role of IL33 in cancer polyploidy contributes to intrinsic and extrinsic mechanisms underlying treatment failure.

31 March 2023
Verified
Other
Open access
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Figure S1: Gating strategy for flow cytometric analysis, Figure S2: IL33 knockdown in human cancer cells, Figure S3: Establishment of IL33 transfectants using human cancer cells, Figure S4: The roles of IL17RB+ ILC2s in the IL33+ tumor progression, and Figure S5: Validation of polyploidy of murine cancer cells

31 March 2023
Verified
Other
Open access
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Detailed methods to establish B16-F10 subclones and IL33 transfectants, and materials for RT-PCR, gene knockdown, and flow cytometry

31 March 2023
Verified
Other
Open access
CKChie Kudo-Saito
Chie Kudo-Saito
TMTakahiro Miyamoto
Takahiro Miyamoto
HIHiroshi Imazeki
Hiroshi Imazeki
HSHirokazu Shoji
Hirokazu Shoji
KAKazunori Aoki
Kazunori Aoki
NBNarikazu Boku
Narikazu Boku
Recurrence and treatment resistance are major causes of cancer-associated death. There has been a growing interest in better understanding epithelial–mesenchymal transition, stemness of cancer cells, and exhaustion and dysfunction of the immune system for which numerous genomic, proteomic, microenvironmental, and immunologic mechanisms have been demonstrated. However, practical treatments for such patients have not yet been established. Here we identified IL33 as a key driver of polyploidy, followed by rapid proliferation after treatment. IL33 induction transformed tumor cells into polyploid giant cells, showing abnormal cell cycle without cell division accompanied by Snail deregulation and p53 inactivation; small progeny cells were generated in response to treatment stress. Simultaneously, soluble IL33 was released from tumor cells, leading to expansion of receptor ST2-expressing cells including IL17RB+GATA3+ cells, which promoted tumor progression and metastasis directly and indirectly via induction of immune exhaustion and dysfunction. Blocking IL33 with a specific mAb in murine IL33+ metastatic tumor models abrogated negative consequences and successfully elicited antitumor efficacy induced by other combined treatments. Ex vivo assays using tumor tissues and peripheral blood mononuclear cells of patients with cancer validated the clinical relevancy of these findings. Together, these data suggest that targeting the IL33-ST2 axis is a promising strategy for diagnosis and treatment of patients likely to be resistant to treatments in the clinical settings.Significance:These findings indicate that the functional role of IL33 in cancer polyploidy contributes to intrinsic and extrinsic mechanisms underlying treatment failure.